Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 35
- Registration Number
- NCT03167437
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
- Conditions
- Recurrent Follicular LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Diffuse Large B-Cell LymphomaGrade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed Non-Hodgkin LymphomaRefractory Follicular LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRecurrent Classic Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT03150329
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- University of Miami
- Registration Number
- NCT03022565
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Angimmune LLC
- Target Recruit Count
- 162
- Registration Number
- NCT02943642
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT02836548
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 6
- Registration Number
- NCT02707900
- Locations
- 🇺🇸
University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 124
- Registration Number
- NCT02638090
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Nabil Adra
- Target Recruit Count
- 52
- Registration Number
- NCT02619253
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Indiana University Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02589145
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.